Blog
Understanding the Differences Between GLP1 and GLP2: A Guide to the Glucagon-Like Peptide
Origin and Structure:
GLP1: The Metabolic Regulator
GLP1 (Glucagon-Like Peptide-1) plays a central role in glucose homeostasis and appetite modulation. In research studies, GLP1 has been observed to: Stimulate glucose-dependent insulin secretion. Inhibit glucagon release. Delay gastric emptying. Promote satiety and reduce food intake. Improve pancreatic beta-cell health
These findings have led to the development of GLP1 receptor agonists (GLP1 RAs), which are currently approved for managing type 2 diabetes and obesity. Additionally, GLP1 activity is being investigated for its cardiovascular and anti-inflammatory effects in preclinical and clinical settings.
GLP2: The Intestinal Support Peptide
GLP2 (Glucagon-Like Peptide-2) is primarily involved in intestinal integrity and regeneration. Key functions being studied include: Promoting intestinal epithelial growth. Enhancing nutrient and fluid absorption. Reducing intestinal permeability. Improving mucosal blood flow. Slowing gastric transit and secretion
GLP2 analogs, such as teduglutide, are approved in certain contexts for supporting patients with short bowel syndrome, where enhanced nutrient absorption is critical. The peptides role in gut health has positioned it as an area of growing interest in gastrointestinal research.
GLP1 and GLP2 are proglucagon-derived peptides with non-overlapping biological roles. While GLP1 supports metabolic regulation, GLP2 contributes to gastrointestinal maintenance and repair. Continued study of these peptides may advance new therapeutic strategies in endocrinology and gastroenterology.
Citations:
- Drucker, D. J. (2018). Mechanisms of action and therapeutic application of GLP-1. Cell Metabolism, 27(4), 740756.
- Holst, J. J. (2007). The physiology of glucagon-like peptide 1. Physiol Rev, 87(4), 14091439.
- Drucker, D. J., & Yusta, B. (2014). Physiology and pharmacology of GLP-2. Annu Rev Physiol, 76, 561583.
- Jeppesen, P. B., et al. (2012). Teduglutide therapy for short bowel syndrome. N Engl J Med, 367(7), 527538.
- Nauck, M. A., & Meier, J. J. (2019). Incretin hormones in health and disease. Diabetes Obes Metab, 21(S1), 521.
- Holst, J. J., & Deacon, C. F. (2005). GLP-1 and GLP-2 peptide therapeutics. Br J Clin Pharmacol, 61(6), 601609.
- Habib, A. M., et al. (2012). Proglucagon-derived peptides in glucose regulation. Int J Mol Sci, 13(3), 33063328.
- Estall, J. L., et al. (2009). GLP-1R signaling in metabolic tissues. Endocr Rev, 30(5), 506535.
- Orskov, C., et al. (1994). Tissue biology of proglucagon peptides. Scand J Gastroenterol, 29(199), 6875.
Disclaimer:
This article is for educational purposes only. GLP1 and GLP2 compounds referenced in this article are not intended for human use unless approved by regulatory authorities. Laboratory peptides are strictly for in vitro or animal research under qualified supervision.